LUNG CANCER
LUNG CANCER(英文缩写 LUNG CANCER),ISSN 0169-5002,eISSN 1872-8332 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-21 至 2026-09-21，按本站收录文献的发表日期统计。
指标来源：jcr_cas_ifqb
期刊简介
暂无简介。
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 6.081 | Q1 |
| 2022 | 5.300 | Q2 |
| 2023 | 4.500 | Q1 |
| 2024 | 4.400 | Q1 |
| 2025 | 5.300 | Q1 |
LUNG CANCER 最新收录文献
-
3. Fusion isoform multiplicity and impact on treatment outcomes in ALK-rearranged non-small cell lung cancer with next-generation tyrosine kinase inhibitors.
PMID:作者:日期:2026-10-01ALK-rearranged non-small cell lung cancer (NSCLC) reported controversies regarding the impact the ALK-fused genes on treatment outcome. Fusion isoforms are structural variants of the same fusion transcript. Recent evidence suggests that the presence of multiple isoforms within a single tumor is asso…
-
4. Adjuvant immunotherapy in resectable non-small cell lung cancer with nodal downstaging.
PMID:作者:日期:2026-10-01To determine whether prognosis after neoadjuvant chemo-immunotherapy is better predicted by pretreatment clinical nodal stage or post-treatment pathological nodal status, and whether patients downstaged to ypN0 have outcomes comparable to those with primary N0. We conducted a multicenter retrospecti…
-
5. Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer.
PMID:作者:日期:2026-10-01Epidermal growth factor receptor (EGFR) exon 19 deletion subtypes may be associated with differential survival outcomes following EGFR-tyrosine kinase inhibitor treatment. However, evidence remains scarce, particularly regarding osimertinib, and the underlying biological mechanisms are poorly unders…
-
6. First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial.
PMID:作者:日期:2026-10-01Although emerging agents have broadened the therapeutic landscape for non-small cell lung cancer (NSCLC) harboring HER2 alterations, effective and accessible first-line therapy remains limited. In this single-arm, phase II trial, treatment-naïve patients with stage IIIB-IV NSCLC harboring de novo HE…
-
7. Determinants of lung cancer screening intention among eligible individuals.
PMID:作者:日期:2026-10-01Lung cancer screening (LCS) with low-dose computed tomography (LDCT) reduces mortality, yet uptake among eligible adults remains low. This study examined individual-level determinants of LCS intention among guideline-eligible adults who had never been screened. We analyzed cross-sectional survey dat…
-
8. IL20RB drives non-small cell lung cancer progression and immune evasion via K267‑dependent activation of JAK2 phosphorylation and STAT3 signaling.
PMID:作者:日期:2026-10-01Tumor immune evasion is a pivotal mechanism driving therapeutic resistance and poor prognosis in lung cancer. The interleukin-20 receptor β subunit (IL20RB) is implicated in chronic inflammation and oncogenesis, but its precise function and molecular basis in non-small cell lung cancer (NSCLC) requi…
-
9. Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
PMID:作者:日期:2026-10-01Extensive-stage small cell lung cancer (ES-SCLC) is associated with a high symptom burden and impaired health-related quality of life (HRQoL). This prespecified analysis from the phase 3 DeLLphi-304 trial evaluated patient-reported outcomes (PROs) for tarlatamab versus standard-of-care (SoC) chemoth…
-
10. Large cell neuroendocrine carcinoma of the lung: Current standards, emerging targets, and translational foundations.
PMID:作者:日期:2026-10-01Pulmonary large cell neuroendocrine carcinoma (LCNEC) is one of the most complex and heterogenous clinical entities in thoracic oncology, sharing features with both non-small cell lung cancer (NSLC) and neuroendocrine lung cancers. LCNEC diagnosis and classification relies on evolving histopathologi…